Advertisement vbandhakavi, Author at Pharmaceutical Business review - Page 32 of 53
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

All articles by vbandhakavi 

Diurnal secures second US patent for Chronocort

US 10,166,194, entitled “Hydrocortisone Controlled Release Formulation”, is a patent claiming a method of treatment for adrenal dysfunction, including the diseases congenital adrenal hyperplasia (CAH) and adrenal insufficiency